JCYTE
jCyte is a developer of cell-based technology intended to cure retinitis pigmentosa. The company's therapy used retinal progenitor cells can secrete growth factors to rescue damaged retinal cells which help in treating a degenerative eye disease that ultimately causes blindness enabling, patients afflicted by conditions that lead to blindness, preserve and restore sight. They focused on the application of progenitor cell-based technology in retinal diseases.
JCYTE
Industry:
Biotechnology Health Care Information Technology
Founded:
2012-01-10
Address:
Newport Beach, California, United States
Country:
United States
Website Url:
http://www.jcyte.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3.87 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Apache Global Site Tag
Similar Organizations
BioSilta
BioSilta Ltd, a developer of advanced microbial growth systems,
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Strand Life Sciences
Strand is leading a new generation of healthcare defined by genetic insights into disease.
Current Employees Featured
Founder
Key Employee Changes
Official Site Inspections
http://www.jcyte.com
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "jCyte"
Leadership | Scientific Advisory Board | jCyte Inc.
Given Mr. Morris ’ deep scientific background, his track record of success in GSK’s Global R&D organization, his strong hands-on commercial experience in the international pharmaceutical …See details»
jCyte - Crunchbase Company Profile & Funding
JCyte is a developer of cell-based technology intended to cure retinitis pigmentosa. The company's therapy used retinal progenitor cells can secrete growth factors to rescue damaged …See details»
Center for Breakthrough Medicines (CBM) and jCyte Announce …
KING OF PRUSSIA, Pa., Sept. 20, 2022 --The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing the …See details»
jCyte - Contacts, Employees, Board Members, Advisors & Alumni
JCyte is a developer of cell-based technology intended to cure retinitis pigmentosa. New. Resources. Advanced Search. ... Experience the new Crunchbase, powered by AI . …See details»
jCyte - Funding, Financials, Valuation & Investors - Crunchbase
JCyte is a developer of cell-based technology intended to cure retinitis pigmentosa. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
Center for Breakthrough Medicines (CBM) and jCyte …
Sep 20, 2022 jCyte, Inc. is a clinical-stage biotech company focused on developing its first-in-class regenerative cell therapy, jCell, for retinitis pigmentosa (RP) and other retinal degenerative diseases.See details»
jCyte, Inc. Company Profile | Newport Beach, CA | Competitors ...
Find company research, competitor information, contact details & financial data for jCyte, Inc. of Newport Beach, CA. Get the latest business insights from Dun & Bradstreet.See details»
jCyte Company Profile - Office Locations, Competitors, Revenue
JCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. Its allogeneic product candidate, jCell, is delivered by intravitreal injection …See details»
jCyte, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore jCyte, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 5 news, and 1 literature, Drug:Retinal stem cell therapy (jCyte). ... The statistics for drugs in the …See details»
jCyte: Revolutionizing Treatment for Degenerative Retinal Disorders
Sep 22, 2023 Co-founded by University of California, Irvine professors Henry Klassen, M.D., Ph.D., and Jing Yang, M.D., Ph.D., jCyte is on a mission to commercialize the first allogeneic …See details»
jCyte 2025 Company Profile: Valuation, Funding & Investors
JCyte General Information Description. Developer of cell-based therapeutics intended to cure degenerative retinal disorders. The company's therapy uses retinal progenitor cells that …See details»
jCyte - Overview, News & Similar companies | ZoomInfo.com
JCyte, Inc. is a late-stage clinical development biotech company focused on developing its first-in-class regenerative cell therapy, jCell, for RP and other retinal degenerative disorders. The …See details»
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell …
Feb 21, 2024 jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP Research News Known as retinal progenitors, the company’s jCells® are designed to preserve …See details»
Latest News and Press Releases | jCyte Inc.
JCyte Announces Appointment of Victor Chao as Vice President of CMC Operations. July 6, 2021 jCyte Announces Appointment of Adrian Morris as Chief Development Officer. June 22, 2021 …See details»
Jcyte Inc. - BioCentury Company Profiles - BCIQ
May 16, 2023 Jcyte Inc. - BioCentury Company Profiles for the biopharma industrySee details»
jCyte, Inc. (jCyte, Inc.) - 药物管线_专利_临床试验_投融营收
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc., a pioneering biotechnology company dedicated to preserving and restoring vision in patients with retinitis pigmentosa (RP) and …See details»
jCyte Inc. Announces Promising Results In Retinitis Pigmentosa
Aug 13, 2020 jCyte Inc., a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders, announced today …See details»
jCell Therapy | Retinitis Pigmentosa | Degenerative Retinal ... - jCyte
JCyte’s goal is to make jCell the first approved cell therapy to address this critical unmet medical need, and dramatically improve the lives of patients with this degenerative retinal disease. …See details»
jCyte - Updates, News, Events, Signals & Triggers - Crunchbase
JCyte is a developer of cell-based technology intended to cure retinitis pigmentosa.See details»
Corporate History｜Yakult 90th Anniversary Website
Yakult Honsha is certified as a ‘Certified Health & Productivity Management Organization – White 500' (first year). Yakult is certified for the eighth consecutive year in 2025. Yakult Five is …See details»